Neumora Therapeutics (NMRA) Equity Average (2022 - 2026)

Neumora Therapeutics' Equity Average history runs 5 years deep, the most recent figure standing at $87.3 million for Q1 2026.

• In Q1 2026, Equity Average fell 66.13% year-over-year to $87.3 million; the TTM figure through Mar 2026 stood at $87.3 million (down 66.13% YoY), while the FY2025 annual figure was $195.5 million, down 48.3% from the prior year.
• Equity Average was $87.3 million for Q1 2026 at Neumora Therapeutics, down from $118.0 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $490.9 million in Q4 2023 to a low of -$495.7 million in Q2 2023.
• Historically, Equity Average has averaged $102.0 million across 5 years, with a median of $181.6 million in 2025.
• The sharpest annual moves came in 2024 and 2026: Equity Average surged 82882.78% in 2024, then plunged 66.13% in 2026.
• A 5-year view of Equity Average shows it stood at -$434.4 million in 2022, then surged by 213.0% to $490.9 million in 2023, then sank by 38.09% to $303.9 million in 2024, then slumped by 61.17% to $118.0 million in 2025, then dropped by 26.05% to $87.3 million in 2026.
• The last three Equity Average figures came in at $87.3 million (Q1 2026), $118.0 million (Q4 2025), and $157.5 million (Q3 2025), per Business Quant data.